BEIJING, March 01, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (Nasdaq:BGNE), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced that it will present at the Cowen and Company 36th Annual Health Care Conference in Boston, MA.
John V. Oyler, Founder and Chief Executive Officer, and Howard Liang, Ph.D., Chief Financial Officer and Chief Strategy Officer, will deliver a corporate overview at 2:00 p.m. EST on Monday, March 7, 2016.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.
Media/Investor Contact: Lucy Li, PhD Associate Director of Strategy and Investor Relations 781-801-1800 ir@beigene.com media@beigene.com
